02 March 1998
Peri-operative hemodilution in intracranial aneurysm surgery
Danuta Mitosek-Sabbo, Tomasz Trojanowski, Marian CzochraMed Sci Monit 1998; 4(2): CR292-296 :: ID: 502607
Abstract
Delayed cerebral ischemia is the major cause of death and disability in patients suffering from an aneurysmal subarachnoid hemorrhage (SAH). A method of reducing the risk of ischemic deficits during surgery is based on the improvement of brain microcirculation by means of hemodilution. This study presents 80 patients who underwent surgery due to SAH for ruptured intracranial aneurysms. Fifty were selected and underwent perioperative hemodilution. The other 30 comprised the control group. There were no statistically significant differences in the composition of these groups in regard to the commonly recognized prognostic factors. Moore's method was used to evaluate the circulating blood volume in patients operated on with normovolemic hemodilution. After the induction of anesthesia, 20% of the estimated volume of circulating blood was extracted and replaced by Dextran 70 000 and Ringer solution in equal parts. At the time of aneurysm clipping the hematocrit level was lowered to 0.30. In the control group it equaled 0.37. Blood was retransfused directly after aneurysm clipping or during the peri-operative bleeding. The results of treatment were evaluated at the end of the hospital stay as well as one and six months following discharge using the Glasgow Outcome Scale (GOS). Early results evaluated at the time of discharge were better in the group who were operated on using hemodilution than in the control group (GOS I-II 78% and 63.4% respectively). Surgical treatment of intracranial aneurysms using hemodilution, evaluated 6 months following discharge showed good results (GOS Grade I) in about 10% more of hemodiluted patients then in the control group. The difference was statistically significant. In addition, perioperative hemodilution reduced the need for blood transfusions.
Keywords: peri-operative hemodilution, intracranial aneurysm surgery
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952